Hovione Expands Spray Drying Capacities in the USA and Ireland

Lisbon, Portugal-headquartered Hovione has completed significant expansions in Europe and the USA. The investments at the facilities in East Windsor, New Jersey, and Ringaskiddy, Cork, significantly increase the global capacities of the CDMO (contract development and manufacturing organization) for spray drying for pharma applications and improve the sites' capabilities.

The investment in New Jersey is the first step of a multi-year site expansion program, aimed at advancing both spray drying and tableting capabilities, Hovione said. Simultaneously, the spray drying capacity at the Cork facility was increases nearly twofold.

Jean-Luc Herbeaux, CEO of Hovione said: “These expansions, incorporating our latest technologies, reflect Hovione’s unwavering commitment to innovation and manufacturing service excellence. Strengthening our facilities and teams in the USA and Ireland allows us to better serve our customers and provide flexible supply options for both small- and large-scale programs. By increasing our capacity and enhancing our technological capabilities, we are even better equipped to help our customers bring new and more complex drugs to market.”

According to Hovione, the investments at both sites are part of the company’s long-term strategy to remain at the forefront of pharmaceutical technology.

© werbefoto-burger.ch – stock.adobe
© werbefoto-burger.ch – stock.adobe

Company

Hovione

Sete Casas
2674-506 Loures
Portugal

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read